GlassScriptPhysician profile
Glenn Legler
NPI 1578540886
$5,607.91
in general payments reported to CMS, 2019-2025
28 companies · $625 in 2025
The $625 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $494 · 2021: $804 · 2022: $1,271 · 2023: $922 · 2024: $773 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,320.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,200.53 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $560.40 | 2019-2025 | Tezspire, Airsupra, Farxiga |
| Novo Nordisk INC | $552.29 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $539.99 | 2021-2025 | |
| Pfizer INC. | $408.37 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $373.24 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $314.69 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.38 | 2019-2024 | |
| Lilly USA, LLC | $247.56 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Allergan, INC. | $170.97 | 2019-2020 | |
| Exact Sciences Corporation | $168.11 | 2023-2025 | Cologuard Collection Kit |
| Jazz Pharmaceuticals INC. | $139.88 | 2019-2020 | |
| Mylan Specialty L.P. | $134.67 | 2019-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $87.88 | 2021-2023 | |
| Amgen INC. | $67.72 | 2023-2025 | Repatha, Otezla, Repatha |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $62.10 | 2020 | |
| Merck Sharp & Dohme LLC | $53.13 | 2021-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Genentech USA, INC. | $37.43 | 2019 | |
| Boston Scientific Corporation | $30.80 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $27.95 | 2025 | Neffy |
| Grifols USA, LLC | $23.30 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $21.71 | 2024 | |
| Eisai INC. | $21.55 | 2024 | |
| Azurity Pharmaceuticals, INC. | $19.69 | 2025 | Edarbi |
| Biohaven Pharmaceutical Holding Company LTD. | $19.27 | 2022 | |
| Pulmonx Corporation | $18.06 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Paratek Pharmaceuticals, INC. | $17.64 | 2023 | Nuzyra |
| Sunovion Pharmaceuticals INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Legler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.